Edmond DE Rothschild Holding S.A. lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 32.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 37,707 shares of the biotechnology company’s stock after selling 18,357 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Biogen were worth $8,507,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Biogen in the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA purchased a new position in shares of Biogen in the second quarter valued at about $3,274,304,000. Public Sector Pension Investment Board lifted its position in shares of Biogen by 10,085.8% in the third quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company’s stock valued at $557,042,000 after acquiring an additional 2,441,884 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Biogen by 1,524.5% in the third quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after acquiring an additional 2,041,161 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Biogen in the second quarter worth about $322,640,000. 87.93% of the stock is owned by hedge funds and other institutional investors.
Biogen Trading Up 1.0%
Shares of Biogen stock opened at $249.59 on Friday. Biogen Inc. has a twelve month low of $160.36 and a twelve month high of $261.00. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $236.83 and a 200-day moving average price of $206.86. The firm has a market cap of $36.89 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 2.85 and a beta of 0.10.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same period in the previous year, the business earned $4.81 earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities research analysts anticipate that Biogen Inc. will post 12.46 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Weiss Ratings cut Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, October 29th. Argus raised Biogen from a “hold” rating to a “buy” rating and set a $280.00 price target on the stock in a report on Thursday, October 29th. Wedbush upped their price target on Biogen from $212.00 to $225.00 and gave the stock a “neutral” rating in a research note on Thursday, October 29th. Needham & Company LLC reaffirmed a “buy” rating on shares of Biogen in a report on Wednesday. Finally, Canaccord Genuity Group lifted their price objective on shares of Biogen from $248.00 to $272.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $255.45.
Get Our Latest Stock Report on BIIB
Latest Biogen News
Investors following BIIB have been watching these news items:
- Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with ?-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
- Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
- Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article
Biogen Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Further Reading
- Five stocks we like better than Biogen
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
